Differential expression of osteonectin/SPARC during human prostate cancer progression

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 1140-1149

  Thomas, Regi ^a,b   True, Lawrence D ^b   Bassuk, James A ^a   Lange, Paul H ^a   Vessella, Robert L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEONECTIN;

ARTICLE; CANCER GROWTH; DISEASE ASSOCIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NEOPLASM METASTASIS; OSTEONECTIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 0034019916     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Girard, J. P., and Springer, T. A. Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity, 2: 113-123, 1995.
2. Johnston, I. G., Paladino, T., Gurd, J. W., and Brown, I. R. Molecular cloning of SC1: a putative brain extracellular matrix glycoprotein showing partial similarity to osteonectin/BM40/SPARC. Neuron, 4: 165-176, 1990.
3. Guermah, M., Crisanti, P., Laugier, D., Dezelee, P., Bidou, L., Pessac, B., and Calothy, G. Transcription of a quail gene expressed in embryonic retinal cells is shut off sharply at hatching. Proc. Natl. Acad. Sci. USA, 88: 4503-4507, 1991.
4. Zwijsen, A., Blockx, H., Van Arnhem, W., Willems, J., Fransen, L., Devos, K., Raymackers, J., Van de Voorde, A., and Siegers, H. Characterization of a rat C6 glioma-secreted follistatin-related protein (FRP). Cloning and sequence of the human homologue. Eur. J. Biochem., 225: 937-946, 1994.
5. Alliel, P. M., Perin, J. P., Jolles, P., and Bonnet, F. J. Testican, a multidomain testicular proteoglycan resembling modulators of cell social behaviour. Eur. J. Biochem., 214: 347-350, 1993.
6. Termine, J. D., Kleinman, H. K., Whitson, S. W., Conn, K. M., McGarvey, M. L., and Martin, G. R. Osteonectin, a bone-specific protein linking mineral to collagen. Cell, 26: 99-105, 1981.
7. Mason, I. J., Murphy, D., Munke, M., Francke, U., Elliott, R. W., and Hogan, B. L. Developmental and transformation-sensitive expression of the Spare gene on mouse chromosome 11. EMBO J., 5: 1831-1837, 1986.
8. Soderling, J. A., Reed, M. J., Corsa, A., and Sage, E. H. Cloning and expression of murine SC1, a gene product homologous to SPARC. J. Histochem. Cytochem., 45: 823-835, 1997.
9. Iruela-Arispe, M. L., Lane, T. F., Redmond, D., Reilly, M., Bolender, R. P., Kavanagh, T. J., and Sage, E. H. Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. Mol. Biol. Cell, 6: 327-343, 1995.
10. Kupprion, C., Motamed, K., and Sage, E. H. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J. Biol. Chem., 273: 29635-29640, 1998.
11. Pichler, R. H., Bassuk, J. A., Hugo, C., Reed, M. J., Eng, E., Gordon, K. L., Pippin, J., Alpers, C. E., Couser, W. G., Sage, E. H., and Johnson, R. J. SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro. Am. J. Pathol., 148: 1153-1167, 1996.
12. Sage, E. H., Bassuk, J. A., Yost, J. C., Folkman, M. J., and Lane, T. F. Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca(2+)-binding EF-hand sequence. J. Cell Biochem., 57: 127-140, 1995.
13. Strandjord, T. P., Sage, E. H., and Clark, J. G. SPARC participates in the branching morphogenesis of developing fetal rat lung. Am. J. Respir. Cell Mol. Biol., 13: 279-287, 1995.
14. Latvala, T., Puolakkainen, P., Vesaluoma, M., and Tervo, T. Distribution of SPARC protein (osteonectin) in normal and wounded feline cornea. Exp. Eye Res., 63: 579-584, 1996.
15. Kelm, R. J., Jr., Swords, N. A., Orfeo, T., and Mann, K. G. Osteonectin in matrix remodeling. A plasminogen-osteonectin-collagen complex. J. Biol. Chem., 269: 30147-30153, 1994.
16. Hasselaar, P., and Sage, E. H. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J. Cell Biochem., 49: 272-283, 1992.
17. Lane, T. F., Iruela Arispe, M. L., Johnson, R. S., and Sage, E. H. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J. Cell Biol., 125: 929-943, 1994.
18. Kraemer, M., Tournaire, R., Dejong, V., Montreau, N., Briane, D., Derbin, C., and Binetruy, B. Rat embryo fibroblasts transformed by c-jun display highly metastatic and angiogenic activities in vivo and deregulate gene expression of both angiogenic and antiangiogenic factors. Cell Growth Differ., 10: 193-200, 1999.
19. Bassuk, J. A., Birkebak, T., Rothmier, J. D., Clark, J. M., Bradshaw, A., Muchowski, P. J., Howe, C. C., Clark, J. I., and Sage, E. H. Disruption of the Spare locus in mice alters the differentiation of lenticular epithelial cells and leads to cataract formation. Exp. Eye Res., 68: 321-331, 1999.
20. Lane, T. F., and Sage, E. H. Functional mapping of SPARC: peptides from two distinct Ca+(+)-binding sites modulate cell shape. J. Cell Biol., 111: 3065-3076, 1990.
21. Bellahcene, A., and Castronovo, V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am. J. Pathol., 146: 95-100, 1995.
22. Pone, H., Chastre, E., Prevot, S., Nordlinger, B., Empereur, S., Basset, P., Chambon, P., and Gespach, C. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int. J. Cancer, 64: 70-75, 1995.
23. Massi, D., Franchi, A., Borgognoni, L., Reali, U. M., and Santucci, M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum. Pathol., 30: 339-344, 1999.
24. Porte, H., Triboulet, J. P., Kotelevets, L., Carrat, F., Pr'evot, S., Nordlinger, B., DiGioia, Y., Wurtz, A., Comoglio, P., Gespach, C., and Chastre, E. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin. Cancer Res., 4: 1375-1382, 1998.
25. Rempel, S. A., Ge, S., and Gutierrez, J. A. SPARC: a potential diagnostic marker of invasive meningiomas. Clin. Cancer Res., 5: 237-241, 1999.
26. Ledda, M. F., Adris, S., Bravo, A. I., Kairiyama, C., Bover, L., Chernajovsky, Y., Mordoh, J., and Podhajcer, O. L. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med., 3: 171-176, 1997.
27. Sage, E. H. Terms of attachment: SPARC and tumorigenesis. Nat. Med., 3: 144-146, 1997.
28. Le Bail, B., Faouzi, S., Boussarie, L., Guirouilh, J., Blanc, J. F., Carles, J., Bioulac-Sage, P., Balabaud, C., and Rosenbaum, J. Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J. Pathol., 189: 46-52, 1999.
29. Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., and Paulson, D. F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer, 21: 274-281, 1978.
30. Kaighn, M. E., Shankar Narayan, K., Ohnuki, Y., Lechner, J. F., and Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investig. Urol., 17: 16-23, 1979.
31. Horoszewicz, J. S., Leong, S. S., Chu, T. M., Wajsman, Z. L., Friedman, M., Papsidero, L., Kim, U., Chai, L. S., Kakati, S., Arya, S. K., and Sandberg, A. A. The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res., 32: 115-132, 1980.
32. Thalmann, G. N., Anezinis, P. E., Chang, S., Zhau, H. E., Kim, E. E., Hopwood, V. L., Pathak, S., von Eschenbach, A. C., and Chung, L. W. K. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res., 54: 2577-2581, 1994.
33. Fisher, L. W., Stubbs, J. T., III, and Young, M. F. Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins. Acta. Orthop. Scand., 5(Suppl.): 61-65, 1995.
34. Bassuk, J. A., Baneyx, F., Vernon, R. B., Funk, S. E., and Sage, E. H. Expression of biologically active human SPARC in Escherichia coli. Arch. Biochem. Biophys., 325: 8-19, 1996.
35. Liu, A. Y., True, L. D., LaTray, L., Nelson, P. S., Ellis, W. J., Vessella, R. L., Lange, P. H., Hood, L., and Van Den Engh, G. Cell/cell interaction in prostate gene regulation and cytodifferentiation. Proc. Natl. Acad. Sci. USA, 94: 10705-10710, 1997.
36. Thomas, R., Anderson, W. A., Raman, V., and Reddi, A. H. Androgen-dependent gene expression of bone morphogenetic protein 7 in mouse prostate. Prostate, 37: 236-245, 1998.
37. Porter, P. L., Sage, E. H., Lane, T. F., Funk, S. E., and Gown, A. M. Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem., 43: 791-800, 1995.
38. Hunzelmann, N., Hafner, M., Anders, S., Krieg, T., and Nischt, R. BM-40 (osteonectin, SPARC) is expressed both in the epidermal and in the dermal compartment of adult human skin. J. Investig. Dermatol., 110: 122-126, 1998.
39. Ware, J. L. Prostate cancer progression. Implications of histopathology. Am. J. Pathol., 145: 983-993, 1994.
40. Macintosh, C. A., Stower, M., Reid, N., and Maitland, N.J. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res., 58: 23-28, 1998.
41. Umbas, R., Isaacs, W. B., Bringuier, P. P., Schaafsma, H., Karthaus, H., Oosterhof, G., Debruyne, F., and Schalken, J. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res., 54: 3929-3933, 1994.
42. Umbas, R., Schalken, J. A., Aalders, T. W., Carter, B. S., Karthaus, H. F. M., Schaafsma, H. E., Debruyne, F. M. J., and Isaacs, W. B. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res., 52: 5104-5109, 1992.
43. Morton, R. A., Jr., Ewing, C. M., Watkins, J. J., and Isaacs, W. B. The E-cadherin cell-cell adhesion pathway in urologic malignancies. World J. Urol., 13: 364-368, 1995.
44. Cheng, L., Nagabhushan, M., Pretlow, T. P., Amini, S. B., and Pretlow, T. G. Expression of E-cadherin in primary and metastatic prostate cancer. Am. J. Pathol., 148: 1375-1380, 1996.
45. De, M. A., Knudsen, B., Chan-Tack, K., and Epstein, J. I. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology, 53: 707-713, 1999.
46. Bonkhoff, H., Stein, U., and Remberger, K. Differential expression of α6 and α2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum. Pathol., 24: 243-248, 1993.
47. Knox, J. D., Cress, A. E., Clark, V., Manriquez, L., Affinito, K. S., Dalkin, B. L., and Nagle, R. B. Differential expression of extracellular matrix molecules and the α6-integrins in the normal and neoplastic prostate. Am. J. Pathol., 145: 167-174, 1994.
48. Fornaro, M., Tallini, G., Bofetiado, C. J., Bosari, S., and Languino, L. R. Down-regulation of β1C integrin, an inhibitor of cell proliferation, in prostate carcinoma. Am. J. Pathol, 149: 765-773, 1996.
49. Allen, M. V., Smith, G. J., Juliano, R., Maygarden, S. J., and Mohler, J. L. Downregulation of the β4 integrin subunit in prostatic carcinoma and prostatic intraepithelial neoplasia. Hum. Pathol., 29: 311-318, 1998.
50. Trikha, M., Timar, J., Lundy, S. K., Szekeres, K., Tang, K., Grignon, D., Porter, A. T., and Honn, K. V. Human prostate carcinoma cells express functional αIIb(β)3 integrin. Cancer Res., 56: 5071-5078, 1996.
51. Trikha, M., Raso, E., Cai, Y., Fazakas, Z., Paku, S., Porter, A. T., Timar, J., and Honn, K. V. Role of αII(b)β3 integrin in prostate cancer metastasis. Prostate, 35: 185-192, 1998.
52. Zheng, D. Q., Woodard, A. S., Fornaro, M., Tallini, G., and Languino, L. R. Prostatic carcinoma cell migration via α(v)β3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res., 59: 1655-1664, 1999.
53. Hao, J., Yang, Y., McDaniel, K. M., Dalkin, B. L., Cress, A. E., and Nagle, R. B. Differential expression of laminin 5 (α3 β3 γ2) by human malignant and normal prostate. Am. J. Pathol., 149: 1341-1349, 1996.
54. Pfohler, C., Fixemer, T., Jung, V., Dooley, S., Remberger, K., and Bonkhoff, H. In situ hybridization analysis of genes coding collagen IV α1 chain, laminin β1 chain, and S-laminin in prostate tissue and prostate cancer: increased basement membrane gene expression in high-grade and metastatic lesions. Prostate, 36: 143-150, 1998.
55. Nelson, P. S., Plymate, S. R., Wang, K., True, L, D., Ware, J. L., Gan, L., Liu, A. Y., and Hood, L. Hevin, an antiadhesive extracellular matrix protein, is downregulated in metastatic prostate adenocarcinoma. Cancer Res., 58: 232-236, 1998.
56. Gao, A. C., Lou, W., Dong, J., and Isaacs, J. T. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res., 57: 846-849, 1997.
57. Takahashi, S., Kimoto, N., Orita, S., Cui, L., Sakakibara, M., and Shirai, T. Relationship between CD44 expression and differentiation of human prostate adenocarcinomas. Cancer Lett., 129: 97-102, 1998.
58. Paradis, V., Eschwege, P., Loric, S., Dumas, F., Ba, N., Benoit, G., Jardin, A., and Bedossa, P. De novo expression of CD44 in prostate carcinoma is correlated with systemic dissemination of prostate cancer. J. Clin. Pathol., 51: 798-802, 1998.
59. Murphy-Ullrich, J. E., Lane, T. F., Pallero, M. A., and Sage, E. H. SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin-like region and the Ca(2+)-binding EF-hand. J. Cell Biochem., 57: 341-350, 1995.
60. Everitt, E. A., and Sage, E. H. Overexpression of SPARC in stably transfected F9 cells mediates attachment and spreading in Ca(2+)-deficient medium. Biochem. Cell Biol., 70: 1368-1379, 1992.
61. Tremble, P. M., Lane, T. F., Sage, E. H., and Werb, Z. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J. Cell Biol., 121: 1433-1444, 1993.
62. Gilles, C., Bassuk, J. A., Pulyaeva, H., Sage, E. H., Foidart, J. M., and Thompson, E. W. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res., 58: 5529-5536, 1998.
63. Shankavaram, U. T., DeWitt, D. L., Funk, S. E., Sage, E. H., and Wahl, L. M. Regulation of human monocyte matrix metalloproteinases by SPARC. J. Cell Physiol., 173: 327-334, 1997.
64. Lane, T. F., Iruela Arispe, M. L., and Sage, E. H. Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. J. Biol. Chem., 267: 16736-16745, 1992.
65. Iruela Arispe, M. L., Hasselaar, P., and Sage, H. Differential expression of extracellular proteins is correlated with angiogenesis in vitro. Lab. Investig., 64: 174-186, 1991.
66. Jacob, K., Webber, M., Benayahu, D., and Kleinman, H. K. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res., 59: 4453-4457, 1999.
67. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
68. Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W. G., and Quaranta, V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science (Washington, DC), 277; 225-228, 1997.
69. Senger, D. R., and Perruzzi, C. A. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim. Biophys. Acta, 1314: 13-24, 1996.
70. Kochevar, G. J., Stanek, J. A., and Rucker, E. B. Truncated fibronectin. An autologous growth-promoting substance secreted by renal carcinoma cells. Cancer (Phila.), 69: 2311-2315, 1992.
71. Koeneman, K. S., Yeung, F., and Chung, L. W. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate, 39: 246-261, 1999.